Company Profile
Sera Prognostics Stock Price, News & Analysis
Company overview
Business overview
Sera Prognostics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Sera Prognostics is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Sera Prognostics follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Sera Prognostics sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
SERA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Sera Prognostics’ catalysts are PreTRM adoption, reimbursement, and whether the maternal-health diagnostics platform can keep scaling. The company moves when test utilization and coverage both improve.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Source: Sera Prognostics
- 02
- 03
SERA PROGNOSTICS TO PRESENT AT TD COWEN 46th ANNUAL HEALTH CARE CONFERENCE
Source: Sera Prognostics
- 04
- 05
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
Source: Sera Prognostics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.